Skip to main content
NVDA+0.08%AAPL+0.19%GOOGL-1.07%MSFT+0.52%AMZN+0.38%TSM+1.54%SPCX+1.89%META+0.67%AVGO+0.52%TSLA+0.24%SKHY+3.45%MU-0.37%LLY+0.48%BRK-B+0.31%AMD+1.34%JPM-3.42%WMT+2.49%V-2.14%ASMLa+0.32%XOM+0.25%JNJ-0.10%INTC+1.71%0700.HK-2.35%MA-2.07%ABBV+0.32%1398.HK0.00%ORCL+0.38%CSCO-4.50%CVX-0.61%COST+0.10%BAC-3.04%LRCX+2.87%KO+1.71%AMAT+1.77%AP2d+1.47%CAT-1.04%DELL-4.57%ARM+3.19%PG+1.46%0005.HK+0.13%HSBA.L+0.85%UNH-1.22%GE+0.07%3988.HK-0.33%MS-2.87%1816.HK-0.48%HD+2.74%NFLX-1.64%0939.HK-0.82%PM+1.47%CADCHF-0.68%USDCAD+0.67%GBPCHF-0.65%GBPUSD-0.65%CHFJPY+0.62%USDJPY+0.60%EURUSD-0.58%EURCHF-0.57%AUDCHF-0.48%AUDUSD-0.48%USDMXN+0.45%GBPTRY+0.41%USDPLN+0.41%USDZAR+0.36%NZDCAD+0.36%GBPNZD-0.33%GBPHKD+0.32%NZDUSD-0.31%NZDJPY+0.31%EURNZD-0.30%NZDCHF-0.30%GBPMXN-0.28%USDTHB-0.27%NZDSGD-0.26%EURHKD-0.25%USDDKK+0.25%USDNOK+0.23%AUDSGD-0.21%AUDCAD+0.18%AUDNZD-0.18%USDILS+0.16%EURPLN+0.16%GBPAUD-0.16%USDSGD+0.16%EURSEK-0.15%USDTRY+0.15%PLNJPY-0.14%USDCNH+0.13%AUDNOK-0.13%GBPSGD-0.13%EURCNH-0.12%SGDJPY+0.12%AUDDKK-0.12%AUDJPY+0.12%EURZAR+0.11%USDSEK+0.10%EURSGD-0.09%GBPZAR+0.08%CADJPY-0.08%EURGBP+0.08%CHFSEK-0.08%EURCZK+0.08%EURAUD-0.07%EURCAD+0.06%CHFNOK+0.05%NOKJPY+0.05%GBPJPY-0.04%USDCOP-0.04%GBPCAD+0.03%NZDMXN+0.03%CHFSGD-0.02%USDHKD-0.02%USDCHF-0.02%EURNOK-0.01%EURJPY+0.01%EURDKK0.00%XAGUSD-2.48%GAGUSD-2.48%XPTUSD-2.28%SUGAR-1.51%COCOA-1.48%HG1-1.10%C1-1.09%W1-0.95%GAUUSD-0.90%XAUUSD-0.90%XNGUSD+0.80%UKOIL+0.80%BTCUSD-0.45%ETHUSD-0.76%USDTUSD-0.02%XRPUSD-1.24%SOLUSD-1.13%TRXUSDT+0.33%ZECUSDT+0.44%DOGEUSD-0.83%XMRUSDT-1.29%LINKUSD-1.30%BCHUSDT+3.29%XLMUSD-2.37%UNIUSD+0.32%LTCUSD-0.18%HBARUSDT-1.82%SUIUSD-1.02%TONUSD+16.86%TAOUSDT-1.50%AAVEUSD+1.11%DOTUSDT-3.90%ICPUSDT-0.12%ARBUSDT-3.81%ONDOUSDT-2.48%WLDUSDT-4.12%JUPUSDT-1.93%ATOMUSDT-1.70%INJUSDT+1.05%STXUSDT-2.74%FETUSDT-2.62%TIAUSDT-0.06%SEIUSDT-1.67%PYTHUSDT-1.39%IMXUSDT+0.03%GRTUSDT+4.35%OPUSDT+0.93%WIFUSDT-2.55%IOTAUSDT-0.45%POLUSDT-0.27%FARTCOINUSDT-3.71%AXSUSDT+0.71%EOSUSDT+0.28%DYDXUSDT-0.96%ORDIUSDT-2.01%GALAUSDT-0.23%NOTUSDT-2.88%RONINUSDT-0.79%NVDA+0.08%AAPL+0.19%GOOGL-1.07%MSFT+0.52%AMZN+0.38%TSM+1.54%SPCX+1.89%META+0.67%AVGO+0.52%TSLA+0.24%SKHY+3.45%MU-0.37%LLY+0.48%BRK-B+0.31%AMD+1.34%JPM-3.42%WMT+2.49%V-2.14%ASMLa+0.32%XOM+0.25%JNJ-0.10%INTC+1.71%0700.HK-2.35%MA-2.07%ABBV+0.32%1398.HK0.00%ORCL+0.38%CSCO-4.50%CVX-0.61%COST+0.10%BAC-3.04%LRCX+2.87%KO+1.71%AMAT+1.77%AP2d+1.47%CAT-1.04%DELL-4.57%ARM+3.19%PG+1.46%0005.HK+0.13%HSBA.L+0.85%UNH-1.22%GE+0.07%3988.HK-0.33%MS-2.87%1816.HK-0.48%HD+2.74%NFLX-1.64%0939.HK-0.82%PM+1.47%CADCHF-0.68%USDCAD+0.67%GBPCHF-0.65%GBPUSD-0.65%CHFJPY+0.62%USDJPY+0.60%EURUSD-0.58%EURCHF-0.57%AUDCHF-0.48%AUDUSD-0.48%USDMXN+0.45%GBPTRY+0.41%USDPLN+0.41%USDZAR+0.36%NZDCAD+0.36%GBPNZD-0.33%GBPHKD+0.32%NZDUSD-0.31%NZDJPY+0.31%EURNZD-0.30%NZDCHF-0.30%GBPMXN-0.28%USDTHB-0.27%NZDSGD-0.26%EURHKD-0.25%USDDKK+0.25%USDNOK+0.23%AUDSGD-0.21%AUDCAD+0.18%AUDNZD-0.18%USDILS+0.16%EURPLN+0.16%GBPAUD-0.16%USDSGD+0.16%EURSEK-0.15%USDTRY+0.15%PLNJPY-0.14%USDCNH+0.13%AUDNOK-0.13%GBPSGD-0.13%EURCNH-0.12%SGDJPY+0.12%AUDDKK-0.12%AUDJPY+0.12%EURZAR+0.11%USDSEK+0.10%EURSGD-0.09%GBPZAR+0.08%CADJPY-0.08%EURGBP+0.08%CHFSEK-0.08%EURCZK+0.08%EURAUD-0.07%EURCAD+0.06%CHFNOK+0.05%NOKJPY+0.05%GBPJPY-0.04%USDCOP-0.04%GBPCAD+0.03%NZDMXN+0.03%CHFSGD-0.02%USDHKD-0.02%USDCHF-0.02%EURNOK-0.01%EURJPY+0.01%EURDKK0.00%XAGUSD-2.48%GAGUSD-2.48%XPTUSD-2.28%SUGAR-1.51%COCOA-1.48%HG1-1.10%C1-1.09%W1-0.95%GAUUSD-0.90%XAUUSD-0.90%XNGUSD+0.80%UKOIL+0.80%BTCUSD-0.45%ETHUSD-0.76%USDTUSD-0.02%XRPUSD-1.24%SOLUSD-1.13%TRXUSDT+0.33%ZECUSDT+0.44%DOGEUSD-0.83%XMRUSDT-1.29%LINKUSD-1.30%BCHUSDT+3.29%XLMUSD-2.37%UNIUSD+0.32%LTCUSD-0.18%HBARUSDT-1.82%SUIUSD-1.02%TONUSD+16.86%TAOUSDT-1.50%AAVEUSD+1.11%DOTUSDT-3.90%ICPUSDT-0.12%ARBUSDT-3.81%ONDOUSDT-2.48%WLDUSDT-4.12%JUPUSDT-1.93%ATOMUSDT-1.70%INJUSDT+1.05%STXUSDT-2.74%FETUSDT-2.62%TIAUSDT-0.06%SEIUSDT-1.67%PYTHUSDT-1.39%IMXUSDT+0.03%GRTUSDT+4.35%OPUSDT+0.93%WIFUSDT-2.55%IOTAUSDT-0.45%POLUSDT-0.27%FARTCOINUSDT-3.71%AXSUSDT+0.71%EOSUSDT+0.28%DYDXUSDT-0.96%ORDIUSDT-2.01%GALAUSDT-0.23%NOTUSDT-2.88%RONINUSDT-0.79%
JB

Jade Biosciences, Inc. (JBIO)

NASDAQ • Healthcare

$16.76
+$0.02 (+0.1%)
Market closed

Last close at September 22, 2026 at 20:00 UTC

Open$16.92
Day Range$16.6 - $17.16
Avg. Volume (3M)932.7K
Market Cap$1B
52 Week Range
$7.58$28
Next EarningsIn 50 daysNov 12, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$153.2M
EPS (TTM)
-$2.75
ROA (TTM)
-32.46%
Current Ratio
14.93
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

0.0%Q1 2026-$0.45
-9.6%Q2 2026-$0.57
-19.4%Q3 2026-$0.76
Next

Nov 12

in 50 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -19.4%

Jade Biosciences’ earnings missed expectations, with EPS of -$0.76 trailing the -$0.64 estimate by -$0.12, based on preliminary results for the second fiscal quarter of 2026 that were reported August 10, 2026. The biotechnology company generated a GAAP operating loss of about $58.9 million, and net income was a loss of roughly $55.8 million, down 73.5% from a loss of about $32.1 million a year ago. Cash burn remained evident, with negative operating cash flow of around $43.7 million during the quarter as the company continues advancing its kidney-disease pipeline, including lead program JADE-001 for IgA nephropathy alongside preclinical programs JADE-002 and JADE-003. Consensus for the next period calls for EPS of -$0.73.

View full earnings history

About Jade Biosciences, Inc.

Jade Biosciences, Inc. is a NASDAQ-listed biotechnology company developing kidney-disease and earlier-stage therapeutic candidates. Trading as JBIO, the company is a small-cap healthcare name whose pipeline centers on JADE-001 for immunoglobulin A, or IgA, nephropathy, alongside two preclinical programs, JADE-002 and JADE-003.

Name
Jade Biosciences, Inc.
CEO
Tom Frohlich
Website
jadebiosciences.com
Industry
Healthcare
Employees
55

Today's Snapshot

AI-generated

The day ended with JBIO slightly higher at 16.76, while its sector was firmer. Trading was lighter than usual, with volume about half of its usual level.

Trading Volume

Below 10d avg (1.2M)

643.5K

vs S&P 500 Today

Inline with Market

-0.02%

Updated: September 22, 2026 at 20:23 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
JBIO presents broad bearish evidence across momentum, trend and moving averages that supports a strong sell stance. Momentum indicators are weak with a low RSI and a deeply negative CCI, while MACD and price momentum are negative; the ADX shows the move has meaningful trend strength. The stock trades well below its short- and medium-term averages and under the 200-day band, and OBV indicates selling pressure alongside above-normal ATR volatility. Technical takeaway: Strong sell — multiple momentum and trend measures align on bearish pressure with elevated volatility reinforcing the weakness.
All signals
  • EMA (5 indicators)$17.52 - $19.88
    Sell
  • RSI (14)30.37
    Neutral
  • Stochastic %K (14, 3, 3)11.19
    Buy
  • MACD Level (12, 26)-1.24
    Sell

Peers & Related Assets

TECXTectonic Therapeutic, Inc.
$26.5-0.5%
ALDXAldeyra The
$1.4+3.3%
SLNSilence Therapeutics plc
CTNMContineum Therapeutics, Inc.
XOMAXOMA Royalty Corp.
KYTXKyverna Therapeutics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.